Boehringer Mannheim Gmbh

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Carola Dony

Rainer Rudolph

Gunter Schumacher

Dorothea Ambrosius

Thomas F Meyer

Johannes Pohlner

The present invention concerns a process for the isolation of recombinant IgA protease from inclusion bodies. In addition a recombinant DNA is claimed which codes for an IgA protease whose C-terminal helper sequence and preferably also its N-terminal signal sequence is no longer active.

Methods for making neisseria or hemophilus IgA protease and DNA encoding

A process for the activation of recombinant proteins which are present in at least a partially inactive form in which a protein is activated by known solubilization or/and renaturation techniques, said protein having additional helper sequences 2 to 50 amino acids in length at its N- or/and C-terminus whereby the relative hydrophobicity of these helper sequences which is calculated as the sum of the relative hydrophobicity specified in Table 1 for the individual amino acids has a negative numerical value.

Activation of recombinant proteins

Process for the enzymatic cleavage of recombinant proteins using IgA

A granulocyte stimulating factor (G-CSF) or a G-CSF variant differs from natural G-CSF in that one or several amino acids of the sequence ##STR1## at position 50 to 56 of the mature G-CSF with 174 amino acids or at position 53 to 59 of the mature G-CSF with 117 amino acids or/and at least one of the 4 His residues at position 43, 79, 156 or 170 of the mature G-CSF with 174 amino acids position 46, 82, 159 or 173 of the mature G-CSF with 177 amino acids are mutagenized. It is suitable for immunotherapy.

Muteins of the granulocyte colony stimulating factor

Growing community of inventors

Starnberg, Germany

Carola Dony